8-K
filed April 16, 2025, 7:59 PM ET
ticker CARM
CIK 0001485003
other material
confidence high
sentiment negative
materiality 0.75
Carisma Therapeutics Inc. (CARM): Nasdaq/NYSE listing notice — Carisma receives Nasdaq delisting notice for MVLS, MVPHS, bid price non-compliance
Carisma Therapeutics Inc.
- Nasdaq notified Carisma on April 10, 2025, of delisting for failing to maintain $50M MVLS by April 8, 2025 compliance deadline.
- Company also failed $15M MVPHS rule; granted 180 days until October 7, 2025, to regain compliance.
- Existing bid price non-compliance (below $1.00) has compliance period through July 7, 2025.
- Carisma plans to request a hearing before Nasdaq Panel to stay delisting; no assurance of extension.
- Company considering all options but cannot guarantee regaining compliance with any listing rule.
Key facts
Extracted from this filing and checked against the source text.
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
Carisma Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
- Exchange
- nasdaq
- Notice
- deficiency notice
- Deficiency
- minimum bid price
- Rules
- 5450(a)(1)
Exact text from the filing
January 6, 2025, Nasdaq notified the Company that it no longer satisfied Nasdaq Listing Rule 5450(a)(1), which requires the Company to maintain a minimum bid price of $1.00 per share (the “Bid Price Rule” together with the MVLS Rule and the MVPHS Rule, the “Price-based Rules”) for continued listing on The Nasdaq Global Market. In accordance with the Grace Period Rule Nasdaq granted the Company 180 calendar days, through July 7, 2025, to regain compliance with the Bid Price Rule. To evidence compliance with the Price-based Rules, an issuer must evidence compliance with the applicable minimum th
View on SEC.gov
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
Carisma Therapeutics Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(C)).
- Exchange
- nasdaq
- Notice
- deficiency notice
- Deficiency
- market value
- Rules
- 5450(b)(2)(C)
Exact text from the filing
g is held and any extension that the Panel may grant to the Company following the hearing has expired. There can be no assurance that the Panel will grant the Company’s request for continued listing. Also on April 10, 2025, Nasdaq notified the Company that it no longer satisfied Nasdaq Listing Rule 5450(b)(2)(C), which requires the Company to maintain a minimum market value of publicly held shares (“MVPHS”) of $15.0 million (the “MVPHS Rule”) for continued listing on The Nasdaq Global Market. In accordance with the Grace Period Rule, Nasdaq provided the Company 180 calendar days, or until Octo
View on SEC.gov
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
Carisma Therapeutics Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).
- Exchange
- nasdaq
- Notice
- deficiency notice
- Deficiency
- market value
- Rules
- 5450(b)(2)(A)
Exact text from the filing
g is held and any extension that the Panel may grant to the Company following the hearing has expired. There can be no assurance that the Panel will grant the Company’s request for continued listing. Also on April 10, 2025, Nasdaq notified the Company that it no longer satisfied Nasdaq Listing Rule 5450(b)(2)(C), which requires the Company to maintain a minimum market value of publicly held shares (“MVPHS”) of $15.0 million (the “MVPHS Rule”) for continued listing on The Nasdaq Global Market. In accordance with the Grace Period Rule, Nasdaq provided the Company 180 calendar days, or until Octo
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.